Parecoxib Sodium: Analgesia & Organ Protection

Parecoxib Sodium is a water-soluble, injectable sodium salt form of parecoxib, an amide prodrug of the cyclooxygenase II (COX-2) selective, non-steroidal anti-inflammatory drug (NSAID) valdecoxib, with anti-inflammatory, analgesic, and antipyretic activities. Upon intravenous or intramuscular administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2. This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. This NSAID does not inhibit COX-1 at therapeutic concentrations and, therefore, does not interfere with blood coagulation. Parecoxib Sodium is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for pain and has 1 investigational indication.

Parecoxib sodium alleviates ischemia reperfusion

The occurrence of ischemia and subsequent reperfusion (I/R) is unavoidable during organ transplantation. I/R is characterized by cell damage in certain organs under hypoxic conditions, followed by the sudden restoration of oxygenation to tissues, which can cause devastating consequences in transplant recipients. Cyclooxygenase (COX) is a key rate‐limiting enzyme involved in prostaglandin synthesis. COX‐2 is a COX isozyme and is predominantly located at the nuclear membrane; thus, released prostaglandins would preferentially enter the nucleus and regulate gene transcription. Parecoxib sodium (Pare), a nonsteroidal anti‐inflammatory drug commonly used for postoperative pain, is a selective inhibitor of COX‐2. Numerous studies have demonstrated that Pare plays a protective role in various organs, including the brain, heart, liver, and kidneys in I/R animal models. Such a protective role of Parecoxib Sodium is mainly mediated via anti‐inflammation, anti‐oxidation, as well as the regulation of apoptosis, highlighting its superiority and potential value in clinical application. However, whether Pare also exerts the same protective effects against pulmonary I/R and the underlying mechanisms involved have rarely been reported. In the present study, a rat model of pulmonary I/R was established using the noninvasive vessel clamping method to assess the effects of Parecoxib Sodium on I/R injury.[1]

The present study provides insight into this matter, demonstrating that Parecoxib Sodium significantly improved lung ventilation function, attenuated oxidative stress, decreased the inflammatory responses, protected the lungs from I/R‐induced tissue damage, and improved the rat survival rate, possibly via the suppression of ERK/NF‐κB and the activation of the HIF‐1α In conclusion, the present study demonstrated that Pare effectively improved the pulmonary ventilation function, attenuated oxidative stress, protected mitochondrial function, decreased inflammatory responses, attenuated histopathological damage, and enhanced the rat survival rate, possibly via the suppression of ERK/NF‐κB and activation of HIF‐1α signaling, indicating a potential therapeutic effect of Parecoxib Sodium on lung I/R injury. Results from the current study are consistent with an earlier published work. Particularly, we have extensively expanded the research scope and confirmed for the first time the beneficial role of Pare against pulmonary I/R at the mitochondrial, histopathological, and animal levels. However, this study still has certain limitations. For example, what is the underlying mechanism mediating the inductive effect of Pare on HIF‐1α expression? Would this inductive effect on HIF‐1α be also applied to humans? Would preadministration of Parecoxib Sodium produce effective and efficient protection against IR injury during lung transplantation? Further research are urgently needed to answer these questions.

Multiple benefits of parecoxib sodium in perioperative applications

This study focuses on the incidence of POD within 3 days after surgery but does not evaluate the impact of parecoxib sodium on long-term cognitive function. Existing evidence shows that POD is associated with an increased risk of postoperative cognitive dysfunction and dementia, and the neuroprotective mechanisms of parecoxib (such as inhibiting neuroinflammation) may be beneficial for long-term cognition. For example, animal experiments have shown that COX-2 inhibitors can reduce β-amyloid deposition, but this study did not track patients’ cognitive changes after 3 months (only assessed by TICS-M telephone interview). In addition, patients with hyperlipidemia often have comorbid cerebrovascular diseases, and whether parecoxib parecoxib sodium can further protect cognition by improving cerebral blood perfusion still needs to be verified by multi-center studies. The occurrence of POD is related to the timing of inflammatory responses. Increasing multiple samplings during surgery and 48 hours after surgery may more accurately identify high-risk patients. In addition, subgroup analysis showed that parecoxib was more effective in patients with higher PTGS2 levels (P < 0.001), suggesting that baseline inflammation may affect the efficacy. Multiple studies have shown that parecoxib sodium (a selective COX-2 inhibitor) exhibits comprehensive benefits in perioperative applications, including analgesia, anti-inflammation, and reducing the risk of POD. [2]

The study did not analyze the cost-effectiveness of parecoxib, but its clinical promotion needs to balance economy and efficacy. As a selective COX-2 inhibitor, parecoxib is more expensive than traditional NSAIDs, but its benefits in reducing POD (such as shortening hospital stay and reducing nursing costs) have not been quantified. For example, patients with POD have an average prolongation of hospital stay by 2.3 days, and the incidence of POD in the parecoxib group is reduced by 12.39%, which can theoretically save medical expenses. In general, parecoxib sodium (a selective COX-2 inhibitor) demonstrates comprehensive benefits in perioperative applications, including analgesia, anti-inflammation, and reducing the risk of POD. By inhibiting inflammatory factors (such as TNF-α and IL-6) and upregulating anti-inflammatory mediators (such as HO-1 and IL-10), parecoxib sodium significantly reduces the incidence of POD (6.2% vs. 11–27.5%), while also decreasing opioid consumption and pain scores. In addition, preoperative administration is more effective than intraoperative or postoperative administration, with good safety and a lower adverse reaction rate compared to traditional analgesic regimens. These findings support parecoxib sodium as a core drug in multimodal analgesia, particularly suitable for high-risk elderly surgical patients.

Intravenous parecoxib sodium for acute postoperative pain

Parecoxib is the first COX-2 that can be administered parenterally. It is a prodrug (the parent drug is inactive) that is rapidly hydrolysed in vivo to its active form, valdecoxib. Clinical trials have indicated that parecoxib is effective in treating postoperative pain resulting from oral surgery, orthopedic surgery and abdominal hysterectomy pain (Barden 2003). Other studies have demonstrated no significant effects on platelet function or upper gastrointestinal mucosa. As a result, parecoxib sodium has been approved in European countries for the treatment of postoperative pain. In the UK, for example, parecoxib 20 mg or 40 mg powder (and solvent for solution for injection) is licensed for the short-term treatment of postoperative pain. In 2002 concerns were raised about the potential for serious adverse effects from parecoxib because of reactions experienced by some patients to valdecoxib, the active metabolite of parecoxib sodium. These effects included anaphylaxis, angioedema, and serious skin reactions such as toxic epidermal necrolysis, and led to withdrawal of valdecoxib in 2005. As a result, parecoxib is contraindicated in patients who have a history of sensitivity to sulphonamides (a type of antibiotic used to treat infections) because of the risk of severe adverse effects. A previously published systematic review assessed the evidence for the effectiveness of parecoxib for treating postoperative pain from four randomised controlled trials (620 participants) and concluded that parecoxib is an effective analgesic in the postoperative setting. Since then, new studies have been published, and it is hoped that they will provide additional data for more robust estimates of the benefits and harms of parecoxib.[3]

References

[1]Guo J, Yang Y. Parecoxib sodium alleviates ischemia reperfusion-induced pulmonary injury via inhibiting ERK/NF-κB and further activating the HIF-1α pathway. Immun Inflamm Dis. 2022 Sep;10(9):e684. doi: 10.1002/iid3.684. PMID: 36039646; PMCID: PMC9382860.

[2]Geng SM, Wang HX, Xu HC. Multiple benefits of parecoxib sodium in perioperative applications. Int J Surg. 2025 Dec 1;111(12):9954-9955. doi: 10.1097/JS9.0000000000003197. Epub 2025 Aug 21. PMID: 40844892; PMCID: PMC12695373.

Lloyd R, Derry S, Moore RA, McQuay HJ. Intravenous parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2008;(4):CD004771. doi: 10.1002/14651858.CD004771.pub3. PMID: 25267899; PMCID: PMC4176621.

You may like